Trump's fervor for an unproven COVID-19 drug is reportedly fueled by Rudy Giuliani, Dr. Oz

Dr. Oz
(Image credit: Slaven Vlasic/Getty Images for Global Lyme Alliance)

President Trump is very excited about hydroxychloroquine as a treatment for COVID-19, frequently touting it as a "game changer," and he isn't alone in his enthusiasm. His economic adviser Peter Navarro, who reportedly sparred with top U.S. infectious disease expert Dr. Anthony Fauci about hydroxychloroquine, told Fox & Friends on Monday morning he would "bet on President Trump's intuition on this." Other boosters Trump is apparently listening to include his lawyer Rudy Giuliani and Dr. Mehmet Oz, the controversial television personality.

At Sunday night's press briefing, Trump said he hopes doctors use the drug, "because I'll tell you what, what do you have to lose?" He added: "I may take it. I'll have to ask my doctors about that." When a reporter asked Fauci about hydroxychloroquine, Trump stepped in and shut it down.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.